No Data
Bears Are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
Arcutis' ZORYVE (Roflumilast) Awarded Best Eczema Treatment by Glamour
Express News | Arcutis Biotherapeutics Inc : Guggenheim Raises Target Price to $29 From $27
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Arcutis Biotherapeutics Price Target Maintained With a $18.00/Share by Needham
No Data
No Data